...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.
【24h】

Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.

机译:肾移植术后早期和晚期非霍奇金淋巴瘤的免疫抑制及其他危险因素。

获取原文
获取原文并翻译 | 示例

摘要

Non-Hodgkin lymphoma (NHL) incidence is greatly increased after kidney transplantation. NHL risk was investigated in a nationwide cohort of 8164 kidney transplant recipients registered on the Australia and New Zealand Dialysis and Transplant Registry. NHL diagnoses were ascertained using linkage with national cancer registry records. Multivariate Poisson regression was used to compute incidence rate ratios (IRRs) with 95% confidence intervals (CIs) comparing risk by transplant function, and risk factors for early (< 2 years) and late (>/= 2 years) NHL during the first transplantation. NHL occurred in 133 patients. Incidence was strikingly lower after transplant failure and cessation of immunosuppression than during transplant function (IRR, 0.25; 95% CI, 0.08-0.80; P = .019). Early NHL (n = 27) was associated with Epstein-Barr virus (EBV) seronegativity at transplantation (IRR, 4.66; 95% CI, 2.10-10.36, P < .001) and receipt of T cell-depleting antibodies (IRR, 2.39; 95% CI, 1.08-5.30; P = .031). Late NHL (n = 79) was associated with increasing year of age (IRR, 1.02; 95% CI, 1.01-1.04; P = .006), increasing time since transplantation (P < .001), and current use of calcineurin inhibitors (IRR, 3.13; 95% CI, 1.53-6.39; P = .002). These findings support 2 mechanisms of lymphomagenesis, one predominantly of primary EBV infection in the context of intense immunosuppression, and another of dysregulated lymphoid proliferation in a prolonged immunosuppressed state.
机译:肾脏移植后非霍奇金淋巴瘤(NHL)的发生率大大增加。在澳大利亚和新西兰透析与移植注册处注册的8164名肾脏移植受者的全国队列中,对NHL风险进行了调查。通过与国家癌症登记系统记录的联系来确定NHL的诊断。使用多元Poisson回归来计算具有95%置信区间(CI)的发生率比(IRR),比较按移植功能的风险以及在第一次随访中早期(<2年)和晚期(> / = 2年)的危险因素移植。 133例患者发生了NHL。移植失败和停止免疫抑制后的发生率明显低于移植期间(IRR,0.25; 95%CI,0.08-0.80; P = .019)。早期NHL(n = 27)与移植时的爱泼斯坦-巴尔病毒(EBV)血清阴性有关(IRR,4.66; 95%CI,2.10-10.36,P <.001)和接受T细胞耗竭抗体(IRR,2.39) ; 95%CI,1.08-5.30; P = .031)。晚期NHL(n = 79)与年龄增加(IRR,1.02; 95%CI,1.01-1.04; P = .006),移植后的时间增加(P <.001)和当前使用钙调神经磷酸酶抑制剂有关(IRR,3.13; 95%CI,1.53-6.39; P = .002)。这些发现支持两种淋巴瘤发生机制,一种主要是在强烈免疫抑制的情况下原发性EBV感染,另一种是在长期免疫抑制状态下淋巴样增殖失调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号